Incyte INCY
NASDAQ INCY
$126.75 -1.25 (-0.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Incyte (INCY) Interest Expenses (2010 - 2026)

Incyte's (INCY) quarterly Interest Expenses came in at $6.3 million in Q2 2026, up 10.53% YoY from $5.7 million in Q2 2025, and down 1.56% on a QoQ basis from $6.4 million in Q1 2026.

Analysis

Incyte (INCY) Interest Expenses (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Interest Expenses data on file, last reported at $6.3 million in Q2 2026.

  • Quarterly Interest Expenses rose 10.53% year-over-year to $6.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.6 million (down 107.35% YoY) and the FY2025 annual result came in at $22.4 million, down 98.95% from the prior year.
  • Interest Expenses fell to $6.3 million in Q2 2026, from $6.4 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $6.4 million in Q1 2026 to a low of -$14.9 million in Q4 2025.
  • A 5-year average of $2.7 million and a median of $5.0 million in 2022 frame the typical range for Interest Expenses.
  • Annual changes were most pronounced in 2023 — Interest Expenses plunged 1906.45% — and 2024, when it jumped 139.84%.
  • Tracing INCY's Interest Expenses over 5 years: stood at $667000.0 in 2022, then sank by 1906.45% to -$12.0 million in 2023, then surged by 139.84% to $4.8 million in 2024, then sank by 409.83% to -$14.9 million in 2025, then surged by 142.36% to $6.3 million in 2026.
  • The last three Interest Expenses figures came in at $6.3 million (Q2 2026), $6.4 million (Q1 2026), and -$14.9 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Expense (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Incyte 25.44 Bn 20.91 Bn 1.57 Bn 582,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 582,000.00
Mar 31, 2026 569,000.00
Dec 31, 2025 582,000.00
Sep 30, 2025 592,000.00
Jun 30, 2025 594,000.00
Mar 31, 2025 660,000.00
Dec 31, 2024 419,000.00
Sep 30, 2024 774,000.00
Jun 30, 2024 657,000.00
Mar 31, 2024 430,000.00
Dec 31, 2023 804,000.00
Sep 30, 2023 623,000.00
Jun 30, 2023 655,000.00
Mar 31, 2023 469,000.00
Dec 31, 2022 667,000.00
Sep 30, 2022 641,000.00
Jun 30, 2022 678,000.00
Mar 31, 2022 680,000.00
Dec 31, 2021 752,000.00
Sep 30, 2021 439,000.00